ReviewNature reviews. Neurology2010
Update on molecular findings, management and outcome in low-grade gliomas.
Review in Nature reviews. Neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- Clinical, neuroimaging and histopathological features of gliomatosis cerebri: a systematic review based on synthesis of published individual patient data.Journal of neuro-oncology · 2018Pooled it
- Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- Trial
- Lipid metabolism classification of gliomas.Scientific reports · 2026Article
- MRI-Based Machine Learning Fusion Models to Distinguish Encephalitis and Gliomas.Journal of imaging informatics in medicine · 2024Article
- Low-Grade Gliomas: Histological Subtypes, Molecular Mechanisms, and Treatment Strategies.Brain sciences · 2023Review
- Hyaluronic acids mediate the infiltration, migration, and M2 polarization of macrophages: evaluating metabolic molecular phenotypes in gliomas.Molecular oncology · 2022Article
- PTX3 mediates the infiltration, migration, and inflammation-resolving-polarization of macrophages in glioblastoma.CNS neuroscience & therapeutics · 2022Article
- Top-down stepwise refinement identifies coding and noncoding RNA-associated epigenetic regulatory maps in malignant glioma.Journal of cellular and molecular medicine · 2022Article
- Article
- Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes.British journal of cancer · 2021Article
- Predicting factors of tumor progression in adult patients with low-grade glioma within five years after surgery.Translational cancer research · 2021Article
- Prognostic Factors Associated With Survival in Patients With Diffuse Astrocytoma.Frontiers in surgery · 2021Article
- Developing a lncRNA Signature to Predict the Radiotherapy Response of Lower-Grade Gliomas Using Co-expression and ceRNA Network Analysis.Frontiers in oncology · 2021Article
- Prognostic Factors and Nomogram Predicting Survival in Diffuse Astrocytoma.Journal of neurosciences in rural practice · 2020Article
- Identification of Core Genes and Screening of Potential Targets in Glioblastoma Multiforme by Integrated Bioinformatic Analysis.Frontiers in oncology · 2020Article
- Seizure Outcome After Surgical Resection of Insular Glioma.Neurosurgery · 2018Article
- IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.Journal of neuro-oncology · 2017Article
- A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma.The Journal of clinical investigation · 2017Article
- Ranking Novel Regulatory Genes in Gene Expression Profiles using NetExpress.Proceedings of the ... Symposium on Applied Computing. Symposium on Applied Computing · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-grade infiltrating gliomas in adults include diffuse astrocytoma, oligoastrocytoma and oligodendroglioma. The current gold standard diagnosis of these tumors relies on histological classification; however, emerging molecular abnormalities discovered in these tumors are playing an increasingly prominent part in the process of tumor diagnosis and, consequently, patient management. The frequency and clinical importance of tumor protein p53 (TP53) abnormalities, deletions involving chromosomes 1p and 19q, O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, abnormalities in the PTEN tumor suppressor gene and the BRAF oncogene, and isocitrate dehydrogenase (IDH) mutations have become better defined. Molecular markers have not, historically, had an important role in determining the course of treatment for patients with low-grade gliomas, but ongoing phase III clinical trials incorporate 1p deletion or 1p19q codeletion status-and future trials plan to incorporate MGMT promoter methylation status-as stratification factors. Future trials will need to incorporate IDH mutational status in addition to these factors. Ultimately, molecular marker assessment will, hopefully, improve the accuracy of tumor diagnosis and enhance the effectiveness of treatment to achieve improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.